Switzerland-headquartered GALDERMA GROUP N (GALD.SW) on Wednesday said the United States Food and Drug Administration has approved Restylane Lyft with Lidocaine for yet another indication - this time, for augmentation of the chin region and to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.
Restylane Lyft, a next-generation hyaluronic acid (HA) injectable, developed with NASHA technology, has a firmer gel with minimal modification, closely resembling the skin's natural HA.
In a pivotal clinical trial, Restylane Lyft was found to be safe and effective in improving chin projection three months after initial injection, with results maintained in the majority of patients through 12 months.
Restylane Lyft with Lidocaine is already approved for deep injection into facial tissue to treat moderate to severe facial wrinkles and folds, such as nasolabial folds, to enhance the cheeks, and to correct age-related midface contour deficiencies in adults over 21 years of age. It is also indicated for injection into the dorsal hand to restore volume loss in patients aged 21 and older.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.